tiprankstipranks
Trending News
More News >

Aytu BioPharma’s treatment of Marfan syndrome receives FDA orphan designation

Aytu BioPharma’s (AYTU) treatment of Marfan syndrome, enzastaurin, received FDA orphan designation, according to a post to the agency’s site.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1